Recombinant Expression Vectors With Customizable Promoters
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing antibodies, such as hybridoma techniques, are laborious, uncertain, and limited in application, especially for human antibody production, and existing mammalian expression vectors face challenges in efficiently expressing antibodies due to limitations in promoter and enhancer sequences that affect transcription efficiency.
Innovation Solution
Development of recombinant expression vectors and plasmids with customizable enhancer and promoter sequences that can interact more efficiently with host cell transcription factors, allowing for improved transcription and antibody production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional hybridoma techniques are used for antibody production, then antibody generation is achieved through cell fusion, but the process becomes laborious, uncertain, and limited in application especially for human antibody production
Solution Approach 1:
The patent replaces the mechanical cell fusion process with a molecular biology approach using recombinant DNA technology. Instead of fusing cells to produce antibodies, the invention uses expression vectors containing antibody gene sequences that are transfected into host cells, which then express the antibody proteins directly. This substitution eliminates the laborious hybridoma formation process while enabling human antibody production.
Solution Approach 2:
The patent introduces expression vectors as an intermediary carrier between the antibody genes and the host cells. These vectors contain promoter sequences, enhancer elements, and antibody gene sequences that mediate the transfer and expression of antibody genes in host cells, replacing the direct cell-to-cell interaction required in hybridoma techniques.
2Productivity
If existing mammalian expression vectors are used, then antibody expression is achieved, but transcription efficiency is limited due to suboptimal promoter and enhancer sequences
Solution Approach 1:
The patent optimizes transcription efficiency by modifying key parameters of the expression vector, specifically the promoter and enhancer sequences. The invention uses strong, well-characterized promoter elements and enhancer sequences that are known to drive high-level transcription in mammalian cells, thereby improving both the reliability and yield of antibody production compared to existing vectors.
Solution Approach 2:
The patent applies local quality optimization by selecting specific promoter and enhancer sequences with proven high activity in mammalian expression systems. Rather than using generic or weak regulatory elements, the invention incorporates locally optimized sequences (specific promoter and enhancer regions) that are tailored for maximum transcriptional activity, thereby improving antibody expression levels.
Data Source
AI summary
Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.